Pediatric Drug Market Finds its Own Pathway
From a pharma-industry perspective, the pediatric drug market (which includes infants to young adults under 18), while large, exists in something of a shadow, for the simple reason that most drugs are developed for adult patients, and most uses of those drugs for children are off-label. This well recognized situation has been addressed multiple times over the years with national legislation and FDA policies, but overall, the market still runs on a different track than "conventional" medicine. “Speed to therapy is especially critical when focusing on care for children,” says Jessica Black, director, Reimbursement Strategy and Tactics at Xcenda, a part of AmerisourceBergen. The full article can be read on pages 16-19.